After moving -0.2% during today's evening session, Eli Lilly and Company is now trading at a price of $609.2 per share. On average, analysts give it a target price of $587.74.
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide.
Potential Eli Lilly and Company Investors Should Analyze the Following:
-
Eli Lilly and Company has moved 85.0% over the last year.
-
The company has a price to earnings growth (PEG) ratio of 2.3. A number between 0 and 1 could mean that the market is undervaluing Eli Lilly and Company's estimated growth potential
-
Its Price to Book (P/B) ratio is 49.52
-
Eli Lilly and Company currently returns an annual dividend yield of 0.7%.
Understanding Eli Lilly and Company's Operating Margins
| Date Reported | Total Revenue ($ k) | Operating Expenses ($ k) | Operating Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2023-02-22 | 28,541,400 | -13,631,200 | 28 | 3.7 |
| 2022-02-23 | 28,318,400 | -13,362,300 | 27 | -3.57 |
| 2021-02-17 | 24,539,800 | -12,097,500 | 28 | 7.69 |
| 2020-02-19 | 22,319,500 | -11,808,800 | 26 | -3.7 |
| 2019-02-19 | 21,493,300 | -11,026,300 | 27 | 35.0 |
| 2018-02-20 | 22,871,300 | -12,037,400 | 20 |
Eli Lilly and Company's operating margins have averaged 26.0% over the last 6 years, which is significantly higher than the Pharmaceutical industry average of 12.02%. In addition, the firm's margins benefit from a 6.4% yearly growth rate.
